RTP Mobile Logo
Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting (Video Program)
Released July 2021

Featuring an interview with Dr Arjun Balar. (Video Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of genitourinary cancers.

    LEARNING OBJECTIVES

    • Evaluate the available research database on secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the recommendation of nonresearch treatment options for patients.
    • Explore available data with multimodality therapy for nonmetastatic and metastatic hormone-sensitive prostate cancer in order to design effective treatment plans for patients.
    • Appraise the latest clinical data on available treatment modalities for patients with metastatic CRPC, and apply these findings in the determination of best-practice selection and sequencing of therapies.
    • Recognize the available clinical trial evidence with immune checkpoint inhibitors for nonmetastatic urothelial bladder carcinoma (UBC) to determine the current and potential utility of this strategy in clinical practice.
    • Review available clinical trial data with anti-PD-1/PD-L1 antibodies as first-line and maintenance therapy for patients with metastatic UBC, and optimally incorporate these agents into current management algorithms.
    • Recall the mechanisms of action of and pivotal clinical trial findings with enfortumab vedotin, erdafitinib and sacituzumab govitecan for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these novel compounds would be appropriate.
    • Consider published and emerging research information, clinical investigator perspectives and available guideline recommendations to individualize first-line therapy for patients with advanced renal cell carcinoma (RCC).
    • Appraise available research data and ongoing clinical trials evaluating novel agents and strategies for RCC, and counsel appropriately selected patients about participation in active research protocols.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Arjun Balar, MD
    Associate Professor, Department of Medicine
    Director, Genitourinary Medical Oncology Program
    Medical Director, Clinical Trials Office
    NYU Perlmutter Cancer Center
    New York, New York

    Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Ownership Interest: GT Biopharma Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, and Merck.

    Release date: July 2021
    Expiration date: July 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):